Before getting too excited - suggest its worth comparing half on PCP half results. NOPAT and EPS for 2H18 are flat on 2H17 - all the YOY profit growth occurred in the 1st half of FY18.
So ... the extra promised revenue from new accounts appears to be eaten up via delayed billing and higher costs. This is better than I had thought (I thought NOPAT might fall vs 2H17) - but I want to dig a bit further before considering whether I buy back in (especially as the SP climbed today).
CL1 Price at posting:
$2.24 Sentiment: None Disclosure: Not Held